Seeking Alpha

Novartis' (NVS +1%) AIN457 treatment may significantly improve moderate-to-severe plaque...

Novartis' (NVS +1%) AIN457 treatment may significantly improve moderate-to-severe plaque psoriasis on the hands, feet and nails, Phase II data shows. Around 125M worldwide suffer from plaque psoriasis, a hard-to-treat chronic disease characterized by thick and extensive skin lesions that cause itching, scaling and pain. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector